DURECT Corporation (DRRX)

NASDAQ: DRRX · IEX Real-Time Price · USD
0.578
-0.011 (-1.92%)
At close: Oct 4, 2022 4:00 PM
0.551
-0.028 (-4.82%)
After-hours: Oct 4, 2022 7:46 PM EDT
-1.92%
Market Cap 131.74M
Revenue (ttm) 13.45M
Net Income (ttm) -39.38M
Shares Out 227.76M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 163,246
Open 0.580
Previous Close 0.590
Day's Range 0.564 - 0.608
52-Week Range 0.360 - 1.320
Beta 1.20
Analysts Buy
Price Target 5.44 (+840.5%)
Earnings Date Oct 31, 2022

About DRRX

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-a... [Read more...]

Industry Pharmaceuticals
IPO Date Sep 28, 2000
CEO James Brown
Employees 78
Stock Exchange NASDAQ
Ticker Symbol DRRX
Full Company Profile

Financial Performance

In 2021, DURECT's revenue was $13.98 million, a decrease of -53.58% compared to the previous year's $30.11 million. Losses were -$36.27 million, 6,131.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for DRRX stock is "Buy." The 12-month stock price forecast is 5.44, which is an increase of 840.53% from the latest price.

Price Target
$5.44
(840.53% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Innocoll and DURECT Announce U.S. launch of POSIMIR®

POSIMIR® is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery DURECT recently received an $8 million miles...

1 week ago - PRNewsWire

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

CUPERTINO, Calif. , Sept. 6, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

4 weeks ago - PRNewsWire

Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of -25% and 59.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs

-  Webcast of Earnings Call Today, August 4 th at 4:30 p.m. ET -  Enrollment accelerating in the AHFIRM trial CUPERTINO, Calif.

2 months ago - PRNewsWire

DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4

CUPERTINO, Calif. , July 27, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the mark...

2 months ago - PRNewsWire

6 Penny Stocks With 1,000% Upside Potential

Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance. The post 6 Penny Stocks With 1,000% Upside Potential appeared first on Inve...

Other symbols: AGTCALZNAMPEBRDSCRIS
2 months ago - InvestorPlace

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

CUPERTINO, Calif. , July 5, 2022 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chroni...

2 months ago - PRNewsWire

Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0% and 21.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs

- Webcast of Earnings Call Today, May 4 th at 4:30 p.m. ET - Adding new clinical sites and patient dosing progressing in the AHFIRM trial CUPERTINO, Calif.

5 months ago - PRNewsWire

DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4

CUPERTINO, Calif. , April 27, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the mar...

5 months ago - PRNewsWire

DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit

CUPERTINO, Calif., March 23, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

6 months ago - PRNewsWire

DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference

CUPERTINO, Calif., March 9, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

6 months ago - PRNewsWire

Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 40% and 204.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs

CUPERTINO, Calif., March 7, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2021 and provided a corporate update.

6 months ago - PRNewsWire

DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-...

CUPERTINO, Calif., March 1, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placeb...

7 months ago - PRNewsWire

DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on Mar...

CUPERTINO, Calif., Feb. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2021 financial results and host a conference call ...

7 months ago - PRNewsWire

Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks

Durect (DRRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates coul...

8 months ago - Zacks Investment Research

DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference

CUPERTINO, Calif., Jan. 6, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

8 months ago - PRNewsWire

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

CUPERTINO, Calif. and ATHLONE, Ireland, Dec. 22, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceu...

9 months ago - PRNewsWire

DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Ga...

CUPERTINO, Calif., Dec. 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical indus...

9 months ago - PRNewsWire

DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit

CUPERTINO, Calif., Nov. 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced it will participate in a workshop today at the 5th Annual NASH Summit being held virtually from today through...

10 months ago - PRNewsWire

Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepati...

CUPERTINO, Calif., Nov. 12, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of data at the American Association for The Study of Liver Diseases (AASLD) The Liver ...

10 months ago - PRNewsWire

DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-...

CUPERTINO, Calif., Nov. 10, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first ex-U.S. patient in Australia as part of its AHFIRM randomized, double-blind, placebo...

10 months ago - PRNewsWire

DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) ...

CUPERTINO, Calif., Nov. 8, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D.

10 months ago - PRNewsWire

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -0.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research